[MicroRNAs as a diagnostic tool for lung cancer]

Cuadros Celorrio M, Llanos Méndez A
Record ID 32013000372
Spanish
Authors' objectives: Personalized medicine, in which the patient is studied and treated according to results, is leading to the search for new biomarkers to improve the diagnosis and treatment of diseases, especially cancer. In the case of some tumoral processes it is now possible to make predictions about the likely development of the disease, metastasis, or which treatment will be most effective. The importance of microRNAs (miRNAs) in the field of personalized medicine has increased over the past 10 years, as in many diseases there is a dysregulation of protein activity mediated through miRNAs. miRview ™ squamous measures the expression of the miRNA, hsa-miR-205, using quantitative RT-PCR. The result allows the differentiation of squamous from non-squamous non–small cell lung cancer. A systematic review of the literature was made in the Embase and Medline reference databases, without date limit up to March 2010. In addition, the Centre for Reviews and Dissemination (CRD HTA Database), Cochrane Library and ECRI were examined. The review searched for work on the efficacy of microRNA hsamiR- 205 in the differential diagnosis of the histological subtypes of squamous cell carcinoma and adenocarcinoma of the lung.
Authors' recommendations: From the 102 papers found, 5 studies were selected. Only two studies assessed the analytical validity of miRview™ in patients with non-small cell lung cancer. The sensitivity of the miRNA for the detection of carcinoma was between 96% and 100% and the specificity was between 90% and 100%. The area under the ROC curve was close to unity and the positive and negative probability ratios showed a high diagnostic accuracy (9.6 and 0.04, respectively). Although the quality of the studies was moderate to high, the sensitivity of the diagnostic test may be overestimated as it is a case-control design.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Humans
  • Lung Neoplasms
  • MicroRNAs
Contact
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.